

Coverage Criteria Summary – BCBS of Rhode Island

Minimally Invasive Procedures for Back Pain

Intraosseous radiofrequency nerve ablation of the basivertebral nerve (i.e., Intracept™ Procedure)

BCBS of Rhode Island issued a coverage policy for the Intracept™ Procedure effective **02/01/24 for Medicare Advantage Plans only**. The policy outlines specific details regarding criteria and limitations to meet medical necessity. The requirements should be adhered to closely and documented accordingly in the patient chart to ensure the patient meets medical necessity.

Coverage Criteria & Documentation Requirements:

Basivertebral nerve ablation from L3 through S1 may be considered medically necessary in individuals 18 and over when **ALL** of the following criteria have been met:

- ☐ 1. Chronic lumbar back pain of at least 6 months duration that causes functional deficit measured on a pain or disability* scale, **AND**
- ☐ 2. Documented failure to respond to at least 6 months of non-surgical management**; **AND**
- ☐ 3. Absence of non-vertebrogenic pathology per clinical assessment or radiology studies that could explain the source of the patient's pain, including but not limited to fracture, tumor, infection, or significant deformity; **AND**
- ☐ 4. Evidence of type I or II Modic changes on MRI, such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrosis tissues within the adjacent marrow, hypotensive signals (Type I Modic change), and changes to the vertebral body marrow including replacement or normal bone marrow by fat, and hypertensive signals (Type II Modic change), in 1 or more vertebrae from L3-S1; **AND**
- ☐ 5. Individuals must have undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to thermal destruction of the intraosseous BVN (such screening must include psychological, as well as, physical evaluation). Documentation of the history and careful screening must be available in the patient chart if requested.

*Pain assessment and a disability scale must be obtained at baseline to be used for functional assessment.

(criteria continued on next page)

**Non-surgical management may include, but is not limited to:

- Avoidance of activities that aggravate pain;
- Trial of Chiropractic manipulation
- Trial of Physical Therapy;
- Cognitive support and recovery reassurance;
- Injection therapy – epidural and/or facet;
- Spine biomechanics education;
- Specific lumbar exercise program;
- Home use of heat/cold modalities;
- Low impact aerobic exercise as tolerated;
- Pharmacotherapy (e.g., non-narcotic analgesics, NSAIDs, muscle relaxants, neuroleptics, and narcotics)

NOTE: Thermal destruction of the intraosseous BVN must only be performed once per vertebral body from L3-S1 per lifetime. Up to 4 vertebral bodies may be treated during 1 procedure.

Limitations:

Thermal destruction of the intraosseous basivertebral nerve (e.g., Intracept™ system) is **not covered** in the following:

- Skeletally immature patients (≤ 18 years old);
- Severe cardiac or pulmonary compromise;
- Active systemic infection or local infection at the intended treatment level;
- Bleeding diathesis;
- Pregnancy;
- Primary radicular pain into the lower extremities (defined as nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging);
- Previous lumbar/lumbosacral spine surgery at the intended treatment level (with the exception of discectomy/laminectomy if performed >6 months prior to BVN nerve ablation and radicular pain resolved);
- Primary symptomatic lumbar or lumbosacral spinal stenosis (defined as the presence of neurogenic claudication and confirmed by imaging);
- Diagnosed osteoporosis (T-score of -2.5 or less), spine fragility fracture history, trauma/compression fracture at the intended treatment level, or spinal cancer;

(limitations continued on next page)

- Radiographic evidence of any of the following that correlates with predominant physical complaints:
 - Lumbar/lumbosacral disc extrusion or protrusion >5mm at levels L3-S1;
 - Lumbar/lumbosacral spondylolisthesis > 2mm at any level;
 - Lumbar/lumbosacral spondylolysis at levels L3-S1;
 - Lumbar/lumbosacral facet arthrosis/effusion correlated with facet-mediated pain at levels L3-S1.
- BMI >40;
- Advanced generalized systemic disease that limits quality-of-life (QOL) improvements would require a statement of the objective of treatment in such cases;
- Active, untreated substance abuse disorder

Coding:

CPT Code	Description
64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first two vertebral bodies lumbar or sacral
64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral

References:

<https://www.bcbsri.com/providers/sites/providers/files/policies/2024/01/2023%20Minimally%20Invasive%20Procedures%20for%20Back%20Pain.pdf>

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered. Boston Scientific recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label.

Indications for Use: The Intracept™ Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change). Contraindications - Use of the Intracept Intraosseous Nerve Ablation System is contraindicated in: Patients with severe cardiac or pulmonary compromise, patients with active implantable pulse generators (e.g. pacemakers, defibrillators), patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal), patients with active systemic infection or local infection in the area to be treated, patients who are pregnant, and/or skeletally immature patients (generally ≤ 18 years of age). Refer to the Instructions for Use provided with the Intracept Procedure or www.relievant.com/intracept/ for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Copyright © 2025 by Boston Scientific Corporation or its affiliates. All rights reserved.